August 2026 Research Update

Across these papers, a consistent pattern was that AL amyloidosis can look different depending on which organ is involved, so diagnosis commonly relied on pulling together several types of evidence. Imaging (especially heart imaging) could strongly suggest amyloid, but confirmation and amyloid typeamyloid type: Amyloid type means which protein is forming the amyloid deposits, and it matters because different types have different causes and treatments. often depended on tissue biopsy, sometimes from a non-heart site. Several reports also highlighted that standard blood tests for abnormal proteins can be negative or inconclusive even when AL amyloidosis is present. [1] [2] [3] [4]

For heart involvementheart involvement: In AL amyloidosis, heart involvement means amyloid has built up in the heart. This can affect how the heart fills or pumps and can influence symptoms, treatment choices, and monitoring., echocardiographyechocardiography: An ultrasound scan of the heart that shows its structure and how well it fills and pumps. In amyloidosis it can show thickened heart walls and a stiff heart. patterns supported suspicion in a three-patient seriesthree-patient series: A medical report describing a group of people with a similar condition or treatment, without a separate comparison group., but two patients still needed a heart muscle biopsyheart muscle biopsy: A procedure that removes a tiny piece of heart muscle, usually through a thin tube in a blood vessel, to examine under a microscope. It can confirm the cause of heart disease, such as scarring or protein deposits. because other screening biopsies were negative and advanced amyloid typingadvanced amyloid typing: Amyloid typing is testing done on a tissue sample to identify which protein is making the amyloid deposits, helping choose the right treatment for the specific amyloidosis type. was not available. In a separate single-patient reportsingle-patient report: A medical paper that describes one person's diagnosis, treatment and course, often used to share rare events or unusual findings., the person had reduced heart pumping function and did not show the usual echocardiography pattern, yet a heart biopsy confirmed AL amyloidosis and heart MRIheart MRI: A scan that uses a strong magnet and radio waves, not X-rays, to make detailed pictures of the heart. With contrast dye, it can show patterns suggesting amyloid buildup or scarring in the heart muscle. showed widespread scarring-like changes. Together, these reports show that heart imaging can be helpful but does not always look typical, and biopsy may be needed when the picture is unclear. [1] [2]

Several case reports showed diagnosis being made through tissue outside the heart when heart testing was negative or inconclusive. One patient had cardiac tamponadecardiac tamponade: A dangerous condition where fluid builds up around the heart and squeezes it, making it hard for the heart to fill and pump blood. and constrictive pericarditisconstrictive pericarditis: A condition where the pericardium, the sac around the heart, becomes stiff and limits how the heart fills with blood. This can lead to swelling, belly fluid, and shortness of breath., with no amyloid found in pericardial tissue, but amyloid was later found in a prevertebral mass, supporting systemic AL amyloidosissystemic AL amyloidosis: Systemic amyloidosis is a group of diseases in which misfolded proteins form amyloid deposits that can build up in organs throughout the body. One or more organs may be affected, and deposits can interfere with their function.. Another patient had an ischemic strokeischemic stroke: A stroke caused by a blood clot blocking an artery to the brain, reducing blood flow and oxygen. It can lead to sudden weakness, speech problems, or vision changes. that led to broader evaluation; multiple heart imaging tests suggested cardiac amyloid, while a kidney biopsykidney biopsy: A kidney biopsy is a procedure where a small piece of kidney tissue is removed, usually with a needle, and examined under a microscope to look for the cause of kidney damage. confirmed amyloid with lambdalambda: Lambda is one of the two types of antibody light chain, the other is kappa. In AL amyloidosis, the abnormal light chain that forms amyloid is often a lambda type. protein type even though immunofixationimmunofixation: A blood or urine test that detects and identifies abnormal antibody proteins, including light chains. In AL amyloidosis, it helps with diagnosis and checks whether the abnormal protein remains detectable after treatment. and bone marrow testing were inconclusive. [3] [4]

Kidney and urinary-tract presentations also pointed to the importance of tissue diagnosis. In a kidney-biopsy study of 68 people with diabetes and kidney disease, most had non-diabetic causes, and AL amyloidosis was one of the more frequent non-diabetic diagnoses. In a separate four-case series of ureteral obstruction from rare conditions, one person had localized AL amyloidosislocalized AL amyloidosis: Localized amyloidosis means amyloid builds up in one area of the body rather than throughout the body. This matters because the tests and treatments can differ from systemic amyloidosis. limited to the ureter, confirmed by Congo red stainingCongo red staining: A lab test that uses a dye called Congo red to color amyloid in a tissue sample. Under special polarized light, amyloid shows an apple green glow, helping confirm amyloid is present. and lambda restriction, with no evidence of systemic disease. [5] [6]

Unusual first clues were also reported, including bleeding and skin or fluid findings that triggered targeted testing. One patient developed severe uterine bleeding after a procedure and was found to have heavy protein loss in the urineprotein loss in the urine: Protein in the urine means higher than normal protein leaking into urine, often a sign that the kidneys' filters are damaged or inflamed., abnormal blood protein testing, amyloid in the gastrointestinal tract, and a lambda-restricted plasma cell clone in the bone marrow. Another patient had periorbital bruisingperiorbital bruising: Bruising around the eyes, sometimes called raccoon eyes. In AL amyloidosis, it can happen because fragile small blood vessels bleed easily. ("raccoon eyes") as the only sign, yet testing still showed abnormal lambda proteins and Congo red-confirmed amyloid. In a separate report, AL amyloidosis linked to an IgM-relatedIgM-related: A type of antibody made by B cells, often produced early in an immune response. An abnormal IgM made by one cell clone can be a marker of certain blood disorders. blood cancer was diagnosed quickly from a pleural fluid cell block and confirmed by lymph node biopsy. [7] [8] [9]

Two retrospective studiesretrospective studies: A retrospective study looks back at existing records to study outcomes in a group of people, rather than following them forward from enrollment. focused on recognizing cardiac amyloidosiscardiac amyloidosis: Amyloid buildup in the heart muscle that can make the heart stiff and lead to heart failure or rhythm problems. and on who may be more likely to have AL among people with plasma cell disordersplasma cell disorders: A condition where plasma cells grow or behave abnormally and make an unusual antibody or light chain. In AL amyloidosis, the disorder is the source of the light chains that form amyloid deposits.. One large Mayo Clinic study developed echocardiography-based prediction models for AL and another amyloid type, then tested whether adding an AI-based electrocardiogram scoreAI-based electrocardiogram score: An AI-based electrocardiogram score is a number calculated by an artificial intelligence program from a recording of the heart's electrical activity. It uses patterns in that recording to estimate the likelihood of a condition such as cardiac amyloidosis. improved identification; the added value differed by subtype and performance dropped in a later validationvalidation: The process of checking how well a test, prediction tool, or research finding works. Researchers may use separate data from the original study or data from other groups of people. group. Another study in newly diagnosed multiple myelomamultiple myeloma: A cancer of plasma cells, a type of white blood cell in the bone marrow. It is related to AL amyloidosis because the same kind of cells can make abnormal light chains, but it is a separate disease. found AL amyloidosis in about one-fifth of patients and described patterns that were more common when AL (and especially heart involvement) was present, including lambda type, specific electrocardiogramelectrocardiogram: Also called an ECG, a quick test that records the heart's electrical activity through stickers on the skin. It can show rhythm problems, and in amyloidosis it may show unusually small electrical signals. changes, and higher heart blood markersblood markers: A biomarker is something measurable in the body, like a blood test result, urine test, or scan finding, that helps show what a disease is doing or how treatment is affecting it.. [10] [11]

For patients and caregivers, these papers mainly reinforce that diagnosis is often a step-by-step process because AL amyloidosis can affect different organs and may not show up clearly on any single test. This is most relevant now as background for understanding why clinicians may combine imaging, blood and urine testing, and biopsies from different sites, especially when early results conflict. What remains uncertain from these reports is how well newer prediction toolsprediction tools: A prediction model is a math tool that uses patient information (like age or lab tests) to estimate the chance of a future event, and it can help compare risk across groups in studies. (like AI-assisted electrocardiogram scores) will work outside the health systems where they were developed, and how often atypical imaging patterns occur in the broader AL population. [1] [2] [3] [6] [7] [4] [9] [5] [8] [10] [11]

Overall, the month included one moderate-strength, real-world clinic study about how long dexamethasone (a steroid) was continued in initial treatment, plus two case reports describing specific drug combinations used in less typical situations. The larger study suggested that limiting steroid duration did not reduce later blood or organ responses, while longer exposure was linked with more steroid-related side effects and hospitalizations. [12] [13] [14]

In a retrospective cohort of 216 adults treated with dexamethasone-based first treatment (with or without daratumumab), limiting dexamethasone to 3 months or less had similar overall response ratesoverall response rates: The share of people in a study whose disease improved by at least a preset amount. In AL amyloidosis it usually means the share with at least a partial blood response. at 6 months compared with longer use, while deeper early responses were more common in the shorter-duration group. In the shorter-duration group, adding daratumumab was linked with higher complete response rates, while this difference was not clear when dexamethasone was continued longer. Steroid-related toxicities increased after 6 months, and hospitalizations were more frequent with longer exposure, while overall survivaloverall survival: Time from a defined starting point, such as diagnosis or treatment, until death from any cause. Studies use it to describe how long people remain alive, whether or not their disease worsens. was not clearly different between shorter and longer steroid duration. [12]

One case report described a 68-year-old woman with AL amyloidosis involving bullous skin lesionsbullous skin lesions: Large fluid-filled blisters on the skin, which can happen with some diseases or medicines and may break and leave sore areas. and an enlarged tongue, with signs of early heart involvement, treated with daratumumab plus cyclophosphamidecyclophosphamide: A chemotherapy drug that damages DNA and can kill abnormal plasma cells. In AL amyloidosis, it is used with other medicines to reduce production of amyloid-forming light chains., bortezomibbortezomib: Bortezomib is a proteasome inhibitor. It blocks the proteasome, the waste-disposal system that plasma cells rely on, so abnormal plasma cells die and make fewer light chains., and dexamethasone. After 6 months, she had mild improvement in tongue enlargement and no new blisters. Because this was one person, it cannot show how often others would respond similarly. [13]

Another case report described a 75-year-old man with both AL amyloidosis and POEMS syndrome who had difficult-to-control heart failuredifficult-to-control heart failure: A condition in which the heart cannot pump or fill with blood well enough for the body's needs, causing breathlessness, swelling and tiredness. In AL amyloidosis it usually comes from a stiff, thickened heart. and received 12 cycles of bortezomib, cyclophosphamide, and dexamethasone. He achieved complete blood response and organ response, with normalization of a blood marker used in POEMS syndrome and sustained heart improvement reported over 5 years of follow-up. As a single-patient report, it mainly documents what was done and what happened in that individual situation. [14]

For patients and caregivers, these papers mainly add context about which treatment building blocks were being used and how treatment details (like how long steroids are continued) may relate to side effects and early response depth in real-world care. The strongest evidence here comes from the single-centersingle-center: A single-center study is done at one hospital or clinic, which can make care more consistent but may limit how well results apply to other settings. retrospective study, but it was not randomizednot randomized: Non-randomized means people were not assigned by chance to different study groups. This can make groups differ in important ways that may affect results., so other differences between groups could have influenced results. The case reports may be most relevant as background for people with uncommon presentations (skin blistering, enlarged tongue, or coexisting POEMS syndrome), while uncertainty remains about how broadly those individual outcomes apply. [12] [13] [14]

This month included a single case report focused on teclistamabteclistamab: A bispecific antibody that links T cells (immune cells) to plasma cells by binding CD3 on T cells and BCMA on plasma cells, helping the immune system kill those cells. used after multiple earlier treatments did not work, with repeated heart magnetic resonance imaging over many years. The report highlights that blood responseblood response: In AL amyloidosis, this is how much the abnormal light chain protein in the blood falls with treatment, showing how well treatment is controlling the plasma cells that make it. and organ imaging changes may not move in lockstep, and some scan measures can improve while others suggest ongoing amyloid material may remain. Because it is one patient, it cannot predict typical outcomes. [15]

The case described a 64-year-old man with biopsy-proven cardiac AL amyloidosis who achieved a complete blood response after teclistamab following failure of four prior lines of therapy. Across 9 years and 11 heart magnetic resonance exams, his heart measurements showed a two-phase pattern: worsening through 2020 followed by sustained improvement through 2025 in measures like heart muscle thickness and pumping strain. One scan measure normalized (native T1native T1: A heart MRI measurement, taken without contrast dye, that changes when heart tissue is abnormal. In amyloidosis it is often high because amyloid fills the heart muscle.), while another (extracellular volumeextracellular volume: A heart MRI measurement of how much of the heart tissue is space between the cells. In amyloidosis it rises as amyloid fills that space, so it is used to estimate how much amyloid is in the heart. fraction) increased, which the authors interpreted as possible ongoing amyloid fibril burdenamyloid fibril burden: Amyloid burden means the amount of amyloid protein deposits in tissues or organs, and it matters because higher burden often means more organ damage. despite clearance of the abnormal blood protein. [15]

For patients, this report is most relevant as an example of a newer immune-based treatment being tried after several earlier regimensregimens: A regimen is a planned treatment schedule, including which medicines are used, their timing, and how long treatment lasts. Studies compare different regimens to see how they perform., and it illustrates how long-term heart imaging can show complex patterns even when blood markers improve. It matters now mainly as background because it is a single-person experience rather than a controlled trial, so it does not establish how often teclistamab works or how heart recovery typically unfolds. Important uncertainties include safety details (not reported here) and whether the mixed scan results reflect true remaining amyloid, measurement limits, or both. [15]

Across these studies (mostly retrospective, with one prospective cohortprospective cohort: A prospective study follows people forward in time from when they join the study, collecting outcomes as they happen rather than relying only on past records.), long-term outcomes in AL amyloidosis were not explained by a single factor. Instead, measures reflecting heart involvement, underlying plasma cell biology, and the degree of long-standing kidney damage each helped identify groups with different survival or kidney trajectories. [16] [17] [18] [19] [20]

In 151 newly diagnosed patients followed prospectively, measures of blood vessel function and circulation were linked to how severely the heart was affected. Lower peripheral and central blood pressure, along with combined pressure-and-heart-strain measures, predicted worse survival, suggesting that the way the heart and blood vessels work together can matter for prognosisprognosis: Prognosis means the expected course of a disease over time, such as how it may change and what outcomes are more or less likely. It helps researchers compare risk groups in studies.. [16]

In 517 newly diagnosed patients, a chromosome change in the plasma cells called 1q gain or amplification identified a group with worse long-term overall survival, and this difference was most visible after the first 2 years from diagnosis. Other high-risk chromosome changes commonly used in multiple myeloma did not show clear independent prognostic impact in this AL amyloidosis cohort. [17]

For kidney involvement, two studies highlighted the importance of separating potentially reversible organ dysfunction from more permanent damage. In 63 people with kidney biopsy-proven amyloidosis (mostly AL), more interstitial fibrosisinterstitial fibrosis: Scarring in an organ caused by long term injury or inflammation. Fibrosis can make an organ stiffer and less able to work normally. and tubular atrophy (scarring and shrinkage in kidney tissue) was tied to worse kidney function at baselinebaseline: Baseline means measurements taken at the start of a study, before the study treatment or comparison begins. Later results are compared with the baseline values. and predicted severe kidney impairment, while amyloid subtype did not predict that outcome. [18]

In 76 people with kidney biopsy-proven AL amyloidosis, blood response tended to happen earlier than kidney responsekidney response: In AL amyloidosis, a kidney response means kidney damage has improved after treatment, usually a clear fall in protein leaking into the urine without a major drop in kidney function., and kidney response occurred months later on average. Kidney response was linked to better kidney survivalkidney survival: The length of time the kidneys keep working well enough without needing dialysis or a kidney transplant. It is often used in studies to compare how kidney disease changes over time., and the study noted that some people may not show kidney improvement even after the blood markers improve, possibly because organ recovery is delayed or because chronic damage limits recovery. [19]

Looking farther out, a single-center study of 452 recipients of autologous stem cell transplantautologous stem cell transplant: A treatment in which a person's own blood-forming stem cells are collected, high-dose chemotherapy (usually melphalan) is given to destroy abnormal plasma cells, and the stem cells are then returned to restore the bone marrow. (including people with AL amyloidosis) reported that overall and progression-free survivalprogression-free survival: Progression-free survival is the length of time during and after treatment that a person lives without the condition getting worse, using the study's own rules for what counts as worsening. gradually declined after 10 years, yet a meaningful proportion of transplanted patients were still alive at 20 years. This suggests that very long-term survival is possible for some patients after transplant, while risks continue to accumulate over time. [20]

For patients and caregivers, these results help explain why doctors may talk about prognosis using several layers of information: heart-related circulation measures, plasma cell genetics, and what the kidney tissue shows about chronic scarring can each add context about long-term risk. Some signals (like kidney improvement) may take many months to appear even when blood markers improve, and some studies suggest differences become clearer only years after diagnosis. These studies cannot tell what will happen to any one person, and several findings need confirmation in future prospective work, especially for how kidney response should be used in long-term planning. [16] [17] [18] [19] [20]

This month, the research in uncommon complications looked at problems outside the heart and kidneys during AL amyloidosis care: liver stiffness on scanningliver stiffness on scanning: Liver stiffness measurement is a scan, often using ultrasound, that estimates how stiff the liver is, which can suggest scarring or other changes in the liver., a serious lung fungal infection after stem cell transplant and mild COVID-19, and a lymph fluid leak in the chest. Evidence was limited (one small pilot study and two case reports), so the results mainly add examples and early signals rather than firm rules. [21] [22] [23]

In a small prospective pilot study of 14 people with newly diagnosed systemic amyloidosis (AL and transthyretintransthyretin: Transthyretin (TTR) is a protein made mainly by the liver that carries thyroid hormone and vitamin A; misfolded TTR causes ATTR amyloidosis. TTR also names the gene that holds the instructions for making this protein.-related), ultrasound-based liver stiffness measurement was sometimes elevated even when standard liver blood tests were not clearly abnormal. In this study, 5 of 14 people had liver stiffness above 10 kPa at baseline, and people with AL had higher values, including values above 17.3 kPa despite normal alkaline phosphatasealkaline phosphatase: Alkaline phosphatase is an enzyme made mostly by the liver and bones and measured in routine blood tests. In AL amyloidosis a raised level can signal liver involvement, and its fall is used to judge liver response.. Liver stiffness improved in 60% of treated patients during follow-up, but the test was described as non-specific and needing larger studies for validation. [21]

One case report described a 68-year-old man with AL amyloidosis who developed invasive pulmonary aspergillosisinvasive pulmonary aspergillosis: A serious lung infection caused by the Aspergillus fungus that grows into lung tissue. It mainly affects people with weak immune systems and can cause fever, cough, and breathing problems. 16 weeks after autologous stem cell transplant, shortly after a mild COVID-19 upper respiratory infection. The diagnosis was supported by bronchoscopybronchoscopy: A test where a thin flexible tube with a camera is passed into the airways to look at the lungs and take samples. fluid testing (galactomannangalactomannan: A substance from the cell wall of Aspergillus, a type of mold. A blood or fluid test for galactomannan can help suggest an Aspergillus infection.) and chest CTchest CT: Computed tomography, an imaging test that uses many X-ray pictures to build detailed cross-section images of the body. changes, and he improved with oral voriconazolevoriconazole: An antifungal medicine used to treat serious fungal infections. It works by blocking fungal cell membrane making, which stops the fungus from growing. given for about 11 months with imaging follow-up. As a single-patient report, it shows what can happen in a high-risk setting but cannot estimate how often it occurs. [22]

Another case report described a 74-year-old man with AL amyloidosis who developed chylothoraxchylothorax: A buildup of milky fluid called chyle, which contains fats from the gut, in the space around the lungs, making breathing harder. (a milky pleural fluid leak). Oil-based lymphangiographyOil-based lymphangiography: Lymphangiography is an imaging test that uses contrast dye to show lymph vessels and lymph nodes, which are part of the body system that drains fluid and supports immunity. localized a leak in the anterior mediastinum, and after chest drainage the chylous effusion did not recur, even though kidney-related fluid loss (nephrotic syndromenephrotic syndrome: A kidney problem where large amounts of protein leak into the urine, causing low blood protein and swelling, often in the legs or around the eyes. It can lead to fluid buildup and higher infection or clot risk.) persisted; the patient later died. The authors suggested the lymphangiography method might help both find and seal the leak in some cases, but this is based on one person. [23]

For patients and caregivers, these reports mainly serve as background about less common organ and complication patterns that can come up during AL amyloidosis care, especially during complex periods such as after stem cell transplant. The liver stiffness study suggests an additional, non-invasive way to track possible liver involvementliver involvement: In AL amyloidosis, this means amyloid has built up in the liver, which can cause an enlarged liver or abnormal liver blood tests. It matters because it can affect symptoms and how the disease is tracked. over time, but it is not specific to amyloidosis and needs confirmation in larger groups. The two case reports highlight that serious lung infections and unusual fluid leaks can occur in individual patients, yet it remains uncertain how general these experiences are or which patients are most at risk. [21] [22] [23]

Across these studies, amyloid buildup in AL amyloidosis is described as both a protein-folding problem and a physical-environment problem. One study shows that a light-chain proteinlight-chain protein: A light chain is a piece of an antibody made by plasma cells, with two main types called kappa and lambda. In AL amyloidosis, misfolded light chains clump together and form amyloid deposits in organs. can form amyloid faster when exposed to mechanical forces in tight, vessel-like channels, while another shows that heart deposits taken from a patient can share a conserved structural shape even when they appear in more than one form. Together, this supports the idea that deposits may form through repeatable pathways, but details likely vary by a persons specific light-chain sequence and local conditions. [24] [25]

In a laboratory model, confined, grid-like microchannels meant to mimic networks of small arteries amplified shear-stress driven amyloid starting points (nucleation) from an amyloid-forming light chain linked to heart involvement. The researchers also saw bursts of amyloid signal over time that appeared to change as fibers accumulated and partially blocked the channels, suggesting a feedback loop between deposit growth, local stress, and blockage. This was preclinical work in a controlled setup, not a study in people. [24]

In a separate study using heart amyloid taken from a single person with AL amyloidosis, cryo-electron microscopycryo-electron microscopy: A way to take very detailed pictures of tiny structures by freezing samples and viewing them with an electron microscope. It can be used to study the shape of proteins and amyloid fibers. found two deposit shapes (single and double fiber building blocks) that shared a common underlying fold for an IGLV6-57 light chain. The work also showed that the deposited protein was a shortened (truncated) form with an intact internal chemical link (disulfide bond), and that both shapes may arise from a shared folding route. Because this is based on one patient and limited samples, it may not represent all AL amyloidosis types. [25]

For patients and caregivers, these results mainly add background on why deposits may form in certain organs, especially the heart: the specific light-chain protein structure matters, and physical forces in small, high-flow spaces could influence how quickly deposits begin and expand. This does not change diagnosis or care on its own, and it is still uncertain how well these lab and single-patient tissue findings apply across the wide variety of AL amyloidosis light-chain types and real-world blood vessel conditions.

This month, research on transthyretin (ATTRATTR: A type of amyloidosis caused by misfolded transthyretin (TTR) protein building up as amyloid in organs. It can be inherited (from a gene change) or wild-type (age related, without a gene change).) amyloid screening focused on how to recognize possible heart amyloid earlier and how to avoid confusing it with AL amyloidosis. One paper laid out a practical, step-by-step approach for testing and referral, while another explored whether tissue removed during common hand surgeries could act as an early clue; a separate imaging study highlighted that some heart wall-thickening patterns are not specific to one disease. [26] [27] [28]

A Malaysian expert consensus described an adapted pathway for suspected ATTR-related heart amyloid that prioritizes non-invasive heart scans plus blood and urine testing for abnormal antibody proteins, with biopsy and genetic testinggenetic testing: Testing that looks for inherited or acquired changes in genes using a blood or tissue sample. Results can help confirm a diagnosis, explain risk, or guide treatment choices in some conditions. when needed. It also emphasized confirming the amyloid type (for example, with specialized tissue testing) and using coordinated care across specialties to reduce diagnostic delaydiagnostic delay: The time between the first symptoms and the correct diagnosis. It matters because delays can allow disease and organ damage to progress before treatment starts.. [26]

In a prospective exploratory study of 200 people having hand surgery, amyloid staining was seen more often in trigger finger tissue than in Dupuytren's surgery tissue, and confirmed transthyretin amyloid appeared in 4 of 100 trigger finger samples. Importantly, no one in either surgical group was found to have clinically overt heart amyloid at the time of evaluation, suggesting these tissue signals (when present) may occur before clear heart disease in some people. [27]

A cross-sectional cardiac MRI study compared a heart muscle thickening pattern called asymmetric septal hypertrophyasymmetric septal hypertrophy: Asymmetric septal hypertrophy means the wall between the heart's two lower chambers is thicker than other parts of the heart muscle. This can sometimes obstruct blood leaving the heart. across multiple conditions, including AL amyloidosis and ATTR amyloidosis. The pattern was most common in hypertrophic cardiomyopathyhypertrophic cardiomyopathy: A disease, usually caused by inherited gene changes, in which the heart muscle becomes abnormally thick. This can make it harder for the heart to fill and can block blood flow out of the heart., and after accounting for age, sex, and body size, the excess asymmetry largely disappeared in the non-hypertrophic cardiomyopathy conditions, meaning this imaging pattern alone may not reliably sort ATTR from other causes of thickened heart muscle. [28]

For patients and caregivers affected by AL amyloidosis, this set of papers mainly matters as background about how clinicians try to avoid mislabeling amyloid type when the heart is involved and how screening is being organized in real-world health systems. The guidelineguideline: A written set of recommendations made by medical experts using the best available evidence. Guidelines help standardize diagnosis, testing, and treatment choices. work supports the idea that combining heart imaging with testing for abnormal antibody proteins, and confirming the amyloid type when needed, is central to distinguishing ATTR-related heart amyloid from AL amyloidosis, but it does not provide outcome data. The hand-surgery screening study suggests some non-heart tissues can contain transthyretin amyloid even when heart disease is not yet clinically apparent, but it was exploratory and does not show how often this leads to later heart problems or how it should be used in routine care.